18/09/2026 US FDA approves Inluriyo + Verzenio for ESR1-Mutated ER+/HER2− Metastatic Breast Cancer Japan Approves Keytruda SC, Expanding Global Commercialization of Alteogen's ALT-B4 Platform Amneal Announces US FDA Approval and Launch of Lanreotide Injection US FDA approves Inluriyo + Verzenio for ESR1-Mutated ER+/HER2− Metastatic Breast Cancer (Ref) Eli Lilly announced that the U.S. FDA has granted full approval to Inluriyo (imlunestrant; estrogen receptor antagonist) + Ver

12/05/2026 FDA grants Breakthrough Therapy Designation to Servier’s B7‑H4 ADC Emiltatug Ledadotin (Emi‑Le) for advanced adenoid cystic carcinoma Rigel secures global rights to VEPPANU, the first FDA‑approved oral PROTAC, with strong Phase 3 data in ER+/HER2‑, ESR1‑mutated breast cancer ZUSDURI delivers 64.5% 3‑year event‑free durability in recurrent LG‑IR‑NMIBC FDA grants Breakthrough Therapy Designation to Servier’s B7‑H4 ADC Emiltatug Ledadotin (Emi‑Le) for advanced adenoid